Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase
- Time of issue:2026-02-16
- Views:0
[概述]Recently, Hang Seng Indexes announced the results of the quarterly review of the Hang Seng Index series as of December 31, 2025. Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") have been successfully included in the Hang Seng Composite Index due to their robust operating performance, standardized corporate governance, and continuously growing market capitalization. The relevant adjustments will be implemented after the market close on Friday, March 6, 2026, and take effect from Monday, March 9, 2026. This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, as well as a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable stocks under the Shanghai and Shenzhen Stock Exchange's Hong Kong Stock Connect program.
Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase
[概述]Recently, Hang Seng Indexes announced the results of the quarterly review of the Hang Seng Index series as of December 31, 2025. Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") have been successfully included in the Hang Seng Composite Index due to their robust operating performance, standardized corporate governance, and continuously growing market capitalization. The relevant adjustments will be implemented after the market close on Friday, March 6, 2026, and take effect from Monday, March 9, 2026. This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, as well as a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable stocks under the Shanghai and Shenzhen Stock Exchange's Hong Kong Stock Connect program.
- Categories:News
- Author:
- Origin:
- Time of issue:2026-02-16
- Views:0
Recently, Hang Seng Indexes announced the results of the quarterly review of the Hang Seng Index series as of December 31, 2025. Yither Biotech (Shanghai) Co., Ltd (Yither Bio) and its parent company Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) (stock code: 02627.HK; hereinafter referred to as "Ab&B Bio") have been successfully included in the Hang Seng Composite Index due to their robust operating performance, standardized corporate governance, and continuously growing market capitalization. The relevant adjustments will be implemented after the market close on Friday, March 6, 2026, and take effect from Monday, March 9, 2026. This marks a further increase in the company's coverage and recognition in the Hong Kong capital market, as well as a further enhancement of its influence in the international capital market. The company is also expected to be included in the scope of investable stocks under the Shanghai and Shenzhen Stock Exchange's Hong Kong Stock Connect program.
▋ Focus on core business and continuously deliver on performance
Recently, the application for the marketing of the trivalent influenza virus subunit vaccine developed by our company has been officially approved. Together with our already marketed tetravalent influenza virus subunit vaccine, we have established a dual-line of defense with "tetravalent + trivalent" high-end influenza vaccine products. This precisely aligns with the current dual-track development pattern of the influenza vaccine market, which emphasizes both "greater precision" and "greater comprehensiveness". It also fully validates and demonstrates our company's mature commercialization capabilities.
Meanwhile, the clinical trial application for the mRNA respiratory syncytial virus vaccine under research has been approved by the US Food and Drug Administration (FDA), and simultaneously accepted by the Center for Drug Evaluation of the National Medical Products Administration of China. This is not only another successful output of the company's mRNA technology platform, but also marks the platform's increasing maturity, laying a solid foundation for the company's continuous breakthroughs and product innovations in the field of preventive and therapeutic vaccines in the future.
In the future, the company will continue to focus on its core business, deliver consistent performance, adhere to compliant operations, and repay the trust of its investors with robust results and transparent governance.
▋ Regarding the Hang Seng Composite Index
The Hang Seng Composite Index is one of the flagship indices in the Hong Kong stock market, encompassing 95% of the highest total market capitalization of securities listed on the main board of the Stock Exchange of Hong Kong. It serves as a significant benchmark for reflecting the overall performance of Hong Kong stocks. Being included in the Hang Seng Composite Index signifies that the company has met the stringent standards of Hang Seng Indexes in terms of market capitalization, liquidity, and industry representation.
▋ About Ab&B Bio
Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) is committed to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines utilizing new technological methods. Aiming at international standards, it conducts independent innovative research and development. As of now, it has obtained multiple clinical trial approvals for new drugs and is orderly carrying out clinical trials and NDA submissions.
In the future, Ab&B Bio will continue to adhere to the concept of "innovation-driven and quality-leading", relying on the three-in-one development system of "AI-empowered research and development + intelligent manufacturing + precision marketing", and is committed to providing the public with high-quality vaccine products with higher safety and more comprehensive protection.
Cherish life and safeguard health. Ab&B Bio will continue to work diligently, ensuring that China has access to globally innovative vaccines and the world benefits from China's high-quality vaccines!
▋ About Yither Bio
Yither Bio, established in 2020, is a wholly-owned subsidiary of Ab&B Bio. Since its inception, it has adhered to the founding principle of not simply replicating its parent company's business model. Instead, it has been committed to building an innovative R&D team with an international perspective and world-class capabilities, dedicated to the research, development, and industrialization of innovative vaccines for human use.
As of now, the company has established multiple technical platforms, including recombinant genetic engineering vaccine research platform, mRNA vaccine research platform, polysaccharide conjugate vaccine research platform, and innovative adjuvant research platform. It has also rapidly advanced the research, development, and production of multiple R&D pipelines, such as multivalent pneumococcal conjugate vaccine, recombinant shingles vaccine, recombinant respiratory syncytial virus vaccine, and mRNA poxvirus vaccine.
Scan the QR code to read on your phone
Real time news
Need more help?
Yither Biotech is striving for and committed to producing innovative and quality vaccines to contribute to the development of China’s biomedical industry and the wellness of Chinese and people around the world.
CONTACT
- E-Mail: yue.peng@yitherbiotech.com
- Hotline: +86-021-61639751
- Address: No. 5, Lane 1690, zhangheng Road, Pudong New Area, Shanghai
SHARE
Copyright: Yither Biotechnology Co. Ltd Powered by:www.30.cn SEO
